Survodutide: Side Effects & Safety

Survodutide (BI 456906) is a dual GLP-1 / glucagon receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma. Safety data comes primarily from three Phase 2 trials: an obesity dose-finding trial published in The Lancet Diabetes & Endocrinology 2024, the MASH (liver disease) Phase 2 trial published in NEJM 2024, and a Phase 2 type 2 diabetes dose-finding study.^[1][2]

The safety pattern resembles the GLP-1 class (GI-dominated effects) plus a modest cardiovascular signal characteristic of glucagon-receptor co-agonists. Compared to pure GLP-1 agents (semaglutide, liraglutide), survodutide shows somewhat higher rates of nausea/vomiting during titration and a small heart rate elevation. Phase 3 trials (SYNCHRONIZE for obesity, LIVERAGE for MASH) will provide the long-term safety data needed for FDA review.

Survodutide is not FDA-approved and is not on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda. Survodutide sold in "research peptide" markets is unregulated and is not the clinical-grade molecule from Boehringer / Zealand trials.

Pooled from the obesity and MASH Phase 2 trials at the 4.8 mg weekly dose (Phase 3 lead dose).^[1][2]

No survodutide-related deaths or unexpected serious adverse events have been reported in Phase 2. The discontinuation rate is higher than semaglutide due to the more substantial GI burden, which is the main practical tolerability question for Phase 3.

Glucagon receptor activation adds these effects that pure GLP-1 agonists don't produce:

• Increased hepatic fat oxidation — the desired liver-protective effect, basis for MASH development.
• Increased energy expenditure — helps weight loss.
• Mild heart rate elevation — +3–5 bpm at 4.8 mg.
• Transient ALT elevations — observed in 5–10% of MASH trial patients; typically mild and self-resolving but warrants monitoring during therapy.
• Theoretical glucose elevation — glucagon raises blood glucose at physiological levels, but survodutide's concurrent GLP-1 activity maintains glycemic control in published trials.
• Increased lipolysis — contributes to weight loss but also to transient mild lipid panel changes.

The glucagon component is also what differentiates survodutide from mazdutide (also GLP-1/glucagon, with similar profile) and from tirzepatide (GLP-1/GIP, different mechanism). It is the basis for the MASH indication that pure GLP-1 agonists cannot easily claim.

• Acute pancreatitis: class warning for all GLP-1 family drugs. Low absolute rates in trials but on every class label. Discontinue with persistent severe abdominal pain.
• Thyroid C-cell tumors: rodent C-cell hyperplasia and MTC seen in GLP-1 class toxicology. FDA-approved class members carry boxed warnings. Phase 3 trials and post-market surveillance will determine the survodutide-specific warning.
• Gallbladder events: increased risk of gallstones and cholecystitis with rapid weight loss.
• Acute kidney injury: typically secondary to severe nausea/vomiting/dehydration. Hydration matters.
• Hypoglycemia: uncommon with survodutide monotherapy in non-diabetics; rises sharply when combined with insulin or sulfonylureas.
• Diabetic retinopathy progression: theoretical class effect from rapid HbA1c lowering; survodutide-specific data limited.
• Gastroparesis: emerging GLP-1 class signal in post-market data; should be assumed for survodutide.

• Personal or family history of medullary thyroid carcinoma or MEN 2: precautionary class contraindication.
• Severe gastrointestinal disease (gastroparesis, IBD active flare, recurrent pancreatitis): avoid.
• Type 1 diabetes: not studied; not for primary glucose management.
• Severe hepatic impairment (Child-Pugh C): exposure may be altered; trial data limited. Note: moderate hepatic impairment (MASH) is the intended use case, but Child-Pugh C cirrhosis is different.
• Severe renal impairment: pharmacokinetics not fully characterized.
• Pregnancy: contraindicated.
• Breastfeeding: insufficient data; avoid.
• Active malignancy: discuss with oncology.
• Known hypersensitivity to survodutide or formulation excipients.

Drug interactions

• Insulin / sulfonylureas: reduce dose to avoid hypoglycemia.
• Oral medications (oral contraceptives, levothyroxine, warfarin, narrow-therapeutic-index drugs): delayed gastric emptying alters absorption. Monitor.
• Other GLP-1 family drugs (semaglutide, tirzepatide, retatrutide, liraglutide): do not combine.
• Exogenous glucagon (hypoglycemia rescue therapy): theoretical interaction; consult clinician.
• Drugs affecting liver enzymes: monitor ALT during initial therapy.

• Mild GI symptoms during titration: hold at current dose 1–2 extra weeks before next escalation. Eat smaller meals, avoid high-fat foods, hydrate.
• Severe persistent abdominal pain: stop and evaluate for pancreatitis (lipase, imaging).
• New onset palpitations or exercise intolerance: stop and seek cardiac evaluation.
• Persistent vomiting / dehydration: hold doses, restore volume, evaluate for gastroparesis.
• Elevated liver enzymes on routine labs: usually transient and self-resolving; monitor with repeat labs. Discontinue if ALT > 3× upper limit of normal or persistent symptoms.
• Right upper quadrant pain, jaundice: evaluate for gallbladder disease.
• Vision changes (diabetic patients): ophthalmology evaluation for retinopathy.
• Allergic reaction: discontinue immediately and seek emergency care.

See the survodutide complete guide, dosage protocols, benefits and research, and the complete GLP-1 guide.